Endovascular & Peripheral Vascular Programs
Vascular centers delivering catheter-based treatments for peripheral arterial occlusion, deep vein thrombosis, and venous access in hospital and office-based lab settings.
Market snapshot
These figures describe Vascular Surgery & Vein Care (4.10.28), the segment that Endovascular & Peripheral Vascular Programs sits within — not Endovascular & Peripheral Vascular Programs on its own.
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so vascular and vein care is not separately sized.
Business model & economics
Revenue model
Procedure and OBL reimbursement; cash-pay vein care
Key economics
- Recurring revenue
- Low–Moderate
- EBITDA margin
- 20–30% with OBL ancillaries
- Capex intensity
- Moderate
procedure-driven
Characteristics
- Office-based labs drive procedural economics.
- Cash-pay vein and aesthetic treatment upside.
- OBL reimbursement and utilization scrutiny are risks.
M&A deal context
Who’s acquiring
- PE-backed vascular/vein platforms
- OBL-focused consolidators
- Specialty MSOs
What’s driving deals
- Roll-up for OBL and procedural economics.
- Aging, diabetes, and PAD demand.
- Reimbursement and utilization dynamics.
Find Endovascular & Peripheral Vascular Programs acquisition targets
Search Acquisera’s index for companies classified under Endovascular & Peripheral Vascular Programs (4.10.28.1) and build a targeted deal pipeline.
Search companies